Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03515837
Title Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Cisplatin + Pembrolizumab + Pemetrexed Disodium

Carboplatin + Cisplatin + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN


No variant requirements are available.